Literature DB >> 25827881

Investigation of genomic methylation status using methylation-specific and bisulfite sequencing polymerase chain reaction.

Melanie A Carless1.   

Abstract

Epigenetic modification plays a central role in the regulation of gene expression and therefore in the development of disease states. In particular, genomic methylation of cytosines within CpG dinucleotides is crucial to development, gene silencing, and chromosome inactivation. Importantly, aberrant methylation profiles of various genes are associated with cancer as well as autoimmune disease, psychiatric and neurodegenerative disorders, diabetes, and heart disease. Various methods are available for the detection and quantification of methylation in a given sample. Most of these methods rely upon bisulfite conversion of DNA, which converts unmethylated cytosines to uracil, while methylated cytosines remain as cytosines. Methylation-specific amplification of DNA can be used to detect methylation at one or more (typically up to about 4) CpG sites by using primers specific to either methylated or unmethylated DNA. Alternatively, amplification of both methylated and unmethylated DNA followed by sequencing can be used to detect methylation status at multiple CpG sites. The following chapter provides protocols for bisulfite conversion of DNA, methylation-specific PCR and bisulfite sequencing PCR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25827881     DOI: 10.1007/978-1-4939-2474-5_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation.

Authors:  Shuwen Han; Xi Yang; Yuefen Pan; Quan Qi; Junjun Shen; Huifen Fang; Zhaoning Ji
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

2.  Methylation of SPRED1: A New Target in Acute Myeloid Leukemia.

Authors:  Nan Su; Yujiao Wang; Xianglan Lu; Weihong Xu; He Wang; Wenbin Mo; Hui Pang; Rurong Tang; Shibo Li; Xiaojing Yan; Yan Li; Rui Zhang
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.